Edwin O'Connor

Edwin M. O'Connor

PartnerCo-Chair, Capital Markets
Edwin M. O'Connor
New York
+1 212 813 8853

Edwin O’Connor, a partner in Goodwin’s Life Sciences group and co-chair of the Capital Markets practice, representing public and private companies and investment banks in the life sciences and tech sectors.

Experience

Edwin’s clients include: Aerovate Therapeutics, argenx, BeiGene, C4 Therapeutics, Centessa Pharmaceuticals, Galecto, Hillhouse Capital, Olo, Phreesia and Rapid Micro Biosystems.

  • Aerovate Therapeutics in its $139.8 million initial public offering
  • Centessa Pharmaceuticals in its $379.5 million initial public offering
  • argenx NV in its $1.27 billion, $1.15 billion, $862 million, $806 million, $300 million and $266 million follow-on offerings, and $114 million initial public offering
  • BeiGene in its $2.08 billion registered direct offering, $340 million, $800 million, $201 million and $200 million follow-on offerings, and $158 initial public offering and its $2.7 billion global strategic collaboration with Amgen
  • Galecto in its $85 million initial public offering and $64 million cross over financing
  • Praxis Precision Medicines in its $190 million initial public offering
  • C4 Therapeutics in its $209.76 million initial public offering
  • Hillhouse Capital as lead investor in the $418 million private placement of I-Mab
  • Ascentage Pharma in its $53 million initial public offering on the Hong Kong Stock Exchange
  • Deciphera Pharmaceuticals in its $127 million initial public offering
  • Inotek Pharmaceuticals Corporation in its sale to Rocket Pharmaceuticals, $50 million offering of convertible senior notes, $69 million follow-on offering, $20 million offering of convertible senior notes, and $40 million initial public offering
  • Moderna in its $604 million initial public offering
  • Voyager Therapeutics in its $70 million initial public offering
  • The initial purchasers in Alphatec Holdings’ $316.25 million convertible senior notes offering
  • The underwriters in Rani Therapeutics’ $73.3 million initial public offering
  • The underwriters in Valneva’s $107.6 million initial public offering
  • The underwriters in Finch Therapeutics’ $127.5 million initial public offering
  • The underwriters in Decibel Therapeutics’ $127 million initial public offering
  • The underwriters in Sensei Biotherapeutics’ $133 million initial public offering
  • The underwriters in Opthea’s $128.2 million initial public offering
  • The underwriters in Albireo’s $160 million follow-on offering
  • The underwriters in Freeline Therapeutics’ $158 million initial public offering
  • The underwriters in Royalty Pharma’s $2.5 billion initial public offering
  • The underwriters in Syndax Pharmaceuticals’ $143.8 million and $115 million follow-on offerings
  • The underwriters in Centogene’s $56 million initial public offering
  • The underwriters in follow-on offerings for DBV Technologies
  • The underwriters in Genfit’s $135 million initial public offering
  • The underwriters in PhaseBio Pharmaceuticals’ $46 million initial public offering
  • The underwriters in Evelo Biosciences’ $85 million initial public offering
  • The underwriters in Arsanis’ $40 million initial public offering
  • The underwriters in G1 Therapeutics’ $180 million and $100 million follow-on offerings, and $105 million initial public offering
  • The underwriters in Ovid Therapeutics’ $75 million initial public offering
  • The underwriter in BeyondSpring’s $54 million initial public offering
  • The underwriters in Reata Pharmaceuticals' $60.5 million initial public offering
  • The underwriters in Oncobiologics' $35 million initial public offering

  • Phreesia in its $245.3 million and $174 million follow-on offerings and $167 million initial public offering
  • Saniona in its $65 million cross over financing
  • The underwriters in 1stdibs’ $117.5 million initial public offering
  • The underwriters in Olo’s $517.5 million initial public offering
  • The underwriters in Altair Engineering’s $200 million convertible notes offering, $196 million follow-on offering and $156 million initial public offering
  • The underwriters in Trinseo’s $190 million initial public offering*
  • The underwriters in Paycom Software’s $100 million initial public offering*

* Denotes experience prior to joining Goodwin.

As Vice President in Goldman Sachs’ Investment Banking Division, Edwin advised on several initial public offerings, including:

  • Cornerstone OnDemand’s $137 million initial public offering
  • RPX’s $160 million initial public offering
  • Gigamon’s $128.5 million initial public offering
  • Jive’s $120 million initial public offering
  • Palo Alto Network’s $260 million initial public offering

Professional Experience

Prior to joining Goodwin in 2014, Edwin practiced at Gibson, Dunn & Crutcher. Previously, he was a vice president in the Investment Banking Division of Goldman, Sachs & Co., where he was responsible for the execution of equity and equity-linked offerings across all industry sectors. While at Goldman, Edwin was also a vice president, associate general counsel in the Investment Banking Division’s Legal Group. At Goldman, he worked on transactions occurring in a number of geographies, including New York, Silicon Valley, London, and Hong Kong. Before joining Goldman, he was an associate at Davis Polk & Wardwell in New York and in London.

Credentials

Education

JD1998

University of Pennsylvania Law School

BAEconomics1995

Colgate University

(magna cum laude; Phi Beta Kappa)

Admissions

Bars

  • New York

Recognition & Awards

Edwin was a recommended lawyer for Capital markets: equity offerings by The Legal 500 from 2021-2023

In law school, Edwin served as comments editor of The Journal of International Economic Law.